Improving Inhaled Product Testing: Methods for Obtaining Better In vitro-In vivo Relationships - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Inhaled Product Testing: Methods for Obtaining Better In vitro-In vivo Relationships
Even in an industry in which all product development is complicated by the intricacies of human biology, orally inhaled products (OIP) stand out as singularly demanding.


Pharmaceutical Technology
Volume 37, Issue 2

References

1. Y. Zhang, K. Gilbertson, and W.H. Finlay, J. Aerosol Medicine 20 (3) 227-235 (2007).

2. M. Hamilton and D. Prime, "A Rapid In-vitro Dry Powder Inhaler Device Equivalence Screening Study Using the Hydraulic Lung," poster presentation at Drug Delivery to the Lungs (DDL) 22 (Edinburgh, Scotland, 2011).

3. B. Olsson, et al., Proceedings of Respiratory Drug Delivery 2008 Conference (Phoenix, AZ, 2008), Vol 1, pp. 197-205.

4. B. Olsson, E. Berg, and M. Svensson, Proceedings of Respiratory Drug Delivery 2010 Conference (Orlando, FL, 2010), pp. 225–234.

5. M. Svensson and E. Berg, Proceedings of Respiratory Drug Delivery 2008 Conference (Phoenix, AZ, 2008), pp. 391-394.

6. Y. Zhang, T. L. Chia, and W. Finlay, Aerosol Sci. and Tech. 40 (5), 361-372 (2006).

7. M. Copley, J. Mitchell, and D. Solomon, Inhalation 5 (4) 12-16 (2011).

8. A. Watkins, T. Gerrish, and N. Childerhouse, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 877-882.

9. B. Grgic, W.H. Finlay, and A.F.Heenan, J. Aerosol Sci. 35 (1) 21-32 (2004).

10. Y. Zhou, J. Sun, and Y.S. Cheng, J. Aerosol Med. and Pulmonary Drug Deliv. 24 (6) 277-284 (2011).

11. M. Rahmatalla, et al., J. Aerosol Med. 15 (4) 379–385 (2002).

12. W. Finlay, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 325-336.

13. N.C. Miller, M.J. Maniaci, S. Dwivedi, and G.W. Ward, Proceedings of Respiratory Drug Delivery Conference (Orlando, FL, 2000), pp. 191-196.

14. W. Finlay and M.G. Gehmlich, Intl. J. of Pharmaceutics 210 (1-2) 83-95 (2000).

15. Eur. Ph., 7.3 (Supplement) Chapter 2.9.44, "Preparations for Nebulisation: Characterisation" (EDQM, Strasbourg, France, 2012), 3803-3805.

16. USP 34-NF 29 First Supplement, General Chapter <1601>, "Products for Nebulization–Characterization Tests" (US Pharmacopeial Convention, Rockville, MD, 2011), pp. 4729-4732.

17. D.K. Nadarassan, K.H.Assi, and H. Chrystyn, Eur. J. Pharm. Sci. 39 (5)348-354 (2010).

18. D.Harris, Pharm. Tech. Eur. 19 (9) 29-35 (2007).

19. P. Burnell, et al., J. Aerosol Sci. 29 (8), 1011-1025 (1998).

20. M. Copley, J. Mitchell, E. McAulay and D. Russell-Graham, Inhalation 4 (1) 7-11 (2010).

21. J. Mitchell, et al., J. Aerosol Med. and Pulmonary Drug Deliv. 25 (4) 188-197 (2012).

22. G.Keegan and D.A.Lewis, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 465-468.

23. G.Keegan and D.A.Lewis, Proceedings of Respiratory Drug Delivery 2012 Conference (Phoenix, AZ, 2012), pp. 469-472.

24. S. Newman and H-K. Chan, J. Aerosol Medicine 21 (1) 1-8 (2008).

Mark Copley is sales director at Copley Scientific, Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham, NG4 2JY, UK, Tel: +44 0 115 961 6229, http://www.copleyscientific.com/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here